Transversal Translational Medicine (TTM) at the LIH enhances ability of biomedical stakeholder institutions to work translationally. TTM aims to foster bed-to-bench-to-bed collaborations within LIH, inter-institutionally across Luxembourg and internationally, in view of implementing translational programmes across research topics, supported by specific platforms and infrastructures bridging between fundamental research and real-world healthcare. With the longstanding experience of the Luxembourgish National Centre for Excellence in Research (Parkinson’s disease) (NCER-PD) excellence programme serving as a blueprint for translational bed-to-bench-to-bed cycles, TTM is perfectly positioned to enhance and develop translational initiatives in biomedical research and beyond.
TTM spans three of the main actors of the biomedical ecosystem in Luxembourg: LCSB (University of Luxembourg), LIH and CHL. It is building capacity to link fundamental research to clinical, and to translate clinical research into tangible health benefits for citizens, providing an interface for fundamental, epidemiological and clinical research. TTM is therefore perfectly positioned to enhance and develop translational initiatives in biomedical research and beyond.
TTM bridges the gap between fundamental science and the clinic and beyond into real life healthcare, improving on diagnosis and stratification of chronic conditions. TTM brings together a wealth of expertise, from an experienced team of basic researchers working in experimental patient-based models, through to healthcare professionals who seek to treat unmet needs via research: physician scientists, nurses and neuropsychologists, and many national and international collaborators.
Strategic Research Goals
- TTM aims to foster collaborations and to attract funding for inter-institutional collaboration in Luxembourg and internationally, in view of implementing translational programmes across different disease areas such as oncology or immune conditions, using the NCER-PD programme as inspiration.
- Create an infrastructure to accelerate translational, fundamental and clinical biomedical research into improved diagnostics, therapies and devices for patients
- Be recognised, nationally and internationally, as a model for state-of-the-art research, advancing evidence-based patient care and coordination of integrated care networks
- Develop translational research pipeline across biomedical stakeholders in Luxembourg, integrating platforms such as the Disease Modelling and Screening Platform (DMSP), a high-throughput automated screening platform that enables personalised drug discovery. (Automated Cell Culture Maintenance and High Throughput/High Content Screening Platform web page)
Develop a translational mindset across researchers, students and healthcare practitioners at research institutions and hospitals in Luxembourg and beyond, enhancing the ability to work together for Team Science.
The Fundamental Research Focus of our translational research group at the LCSB is the elucidation of molecular signaling pathways leading to neurodegeneration in Parkinson's disease. Using mutation screenings in a large sample of Parkinson patients, the group has identified novel mutations in genes that are responsible for familial PD and deciphered genetic variants in candidate genes that are associated with sporadic PD.
The Clinical research focus of the group is through National Centre for Excellence in Research – Parkinson’s Disease (NCER-PD) Programme, an initiative of the Luxembourg National Research Fund. The aim is to understand the mechanism of Parkinson’s disease to enable an earlier diagnosis and to develop precision treatments for PD patients.
Via coordination of integrated care programmes such as ParkinsonNet, TTM provides an immediate return to the citizens and reaches into the community creating access to therapies and implementing prevention strategies.
Prof. Dr med. Rejko Krüger is Director of TTM at the LIH and concurrently also Professor of Neuroscience at the University of Luxembourg. His clinical and experimental research on Parkinson’s disease is supported by an Excellence Grant (PEARL) from the Fonds National de Recherche (FNR). His clinical and research experience extends over 20 years with a special interest focus in the genetics of neurodegenerative diseases, which has resulted in more than 150 scientific publications thus far (>20.000 citations, h-index 49). He coordinates the National Center for Excellence in Research on Parkinson’s disease (NCER-PD), funded by the FNR. Furthermore, he sees patients with Movement Disorders at the Centre Hospitalier de Luxembourg.
[The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
- Transversal Translational Medicine
The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides.
- Immuno-Pharmacology and Interactomics
- Immune Endocrine and Epigenetics
- Transversal Translational Medicine
- Allergy and Clinical Immunology